GlobeNewswire

Reselling Microsoft 365: New Opportunities with Microsoft's Visionary New Platform, AppRiver says

Dela

 

 

NOTE: The following article contains content from AppRiver. AppRiver could soon become even  more interesting for Swiss managed service providers. As AppRiver, in the next few weeks,  is very likely to be the first provider in Switzerland with Microsoft 365 on the market.

GULF BREEZE, Fla., May 17, 2018 (GLOBE NEWSWIRE) -- Microsoft 365 represents the fulfillment of Microsoft's longstanding vision to deliver an innovative portfolio of productivity, collaboration and security tools that address the future of business. It is the culmination of Microsoft's innovation, technology and forward strategy, and it will revolutionize how business users work and how administrators manage their IT infrastructure.

Microsoft looked deep into its crystal ball and saw how the modern workplace was drastically transforming. The future is cloud-based. It's mobile. It's global and dispersed. It's not tied to a formal office. And it's not secure.

For managed service providers (MSPs), consultants and resellers, Microsoft 365 presents a collection of enhanced business opportunities that will not only help to sell subscriptions, but also to educate clients and support the new infrastructure.
                                                            
Partners will need to develop a fluent understanding of the features, benefits and shortcomings of Microsoft 365 before making client presentations or recommendations. While Microsoft has generously provided a great deal of information on Microsoft 365, it can be a significant task to sort through the available assets and determine which are applicable.

Begin developing your knowledge of Microsoft 365 by understanding:

  • What Microsoft 365 encompasses
  • Key security considerations
  • New service and business opportunities

Microsoft 365: What's "In the Box"?
Many assume that Microsoft 365 is a new branding approach for the popular Office 365 suite of solutions. It isn't. Even at its most basic, Microsoft 365 is the applications, management tools and the operating system combined as one. It's a union that, at a glance, may seem unwieldy. However, its complexity is designed to transform the workplace for the better.

For partners, their clients and IT professionals, it is valuable to think of Microsoft 365 as a practice, not a product. While Microsoft 365 will have a significant impact on business users, it will be an entire shift in how IT administrators manage technology and their users. In turn, partners also need to take a different approach when presenting Microsoft 365 to clients.

Securing Microsoft 365
Microsoft 365 radically changes the security footprint and foundation. With Microsoft 365, all the pieces are working in concert and receive structured updates that are compatible with the entire stack. Among the many enhancements, Microsoft recognized that security can't be effectively addressed at only the enterprise or IT level, since end-users can infect the network with the click of a bad link. Therefore, Microsoft intelligently moved security to the user level and partners need to educate their clients on how to use these new tools.

Microsoft 365 outperforms legacy operating systems with a secure, modern state that extracts the best of Microsoft's new security capabilities. Moreover, while Microsoft 365 offers a wide range of security enhancements above and beyond Office 365, it will still require additional protections and will demand heightened monitoring and maintenance.

Microsoft 365: The Channel Opportunity
Beyond the opportunity to sell new subscriptions to customers, Microsoft 365 provides channel partners with a new opportunity to deliver ongoing service and support, along with the necessary hardware and security software that will power the next-generation, secure enterprise.

From a financial perspective, Microsoft 365 carries a higher perceived price point than Office 365, so gross margins will likely increase if partners apply the same markup methodology. Partners should expect a 10 - 18 percent increase in earnings over typical managed services.

Since Microsoft 365 is still new and there is much confusion in the market, partners can expect to receive many questions from clients. Some clients will also raise objections about the move to Microsoft 365 by attempting to hang on to current or legacy operating systems as long as possible.

Based on Microsoft's impassioned approach and the widespread benefits that Microsoft 365 will deliver, the upgrade to Microsoft 365 is essentially inevitable. It's not about if, it's when since many end-of-life (EOL) events are already scheduled to occur by the end of 2020. And while Microsoft has been known to extend EOL deadlines in the past, the transitions to Microsoft 365 and reseller opportunities will happen soon.

Next Steps: Getting Started
The need to get up-to-speed quickly on Microsoft 365's intricacies cannot be overstated. Few have time to sort through the bulk of Microsoft materials and extract the most actionable items, so it's helpful to locate materials, podcasts and videos that act as an "interpreter" to help decipher Microsoft's marketing language and support documentation for you and your customers.

There are also complimentary courses to help partners learn and sell Microsoft 365, some of which result in a certification medallion - a key element of validation that IT decision-makers will seek when selecting expert Microsoft 365 resellers.

Develop your knowledge, then get ready for the new era of opportunities with selling and supporting Microsoft's visionary new platform to IT decision-makers.

-----------------------------------
About the Author
Scott Paul is the Senior Director of AppRiver's Microsoft Alliance. AppRiver was one of the Microsoft's original go-to-market partners for Office 365 and now has one of the most experienced Office 365 support teams in the business. The company also provides free Microsoft 365 training courses for channel partners.
                                                       

CONTACT INFORMATION:

Jordi Vilanova
AppRiver
jvilanova@appriver.com
34-932-200-101 Ext 1002




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AppRiver via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum